The purpose of this study is to compare a usual treatment using Pembrolizumab in combination with a newer treatment Sacituzumab Govitecan compared to usual physician directed standard treatment options.
Learn more about the EA8231 or call the Reading Hospital Cancer Research Office at 484-628-8193.
